IP Library Granted Patent US 10,743,801
Granted Patent B2
US 10,743,801 · App. 16/691,252 · Granted Aug 18, 2020

System and methods for processing analyte sensor data for sensor calibration

Inventors: Apurv Ullas Kamath (San Diego, CA); James H. Brauker (Addison, MI); Paul V. Goode, Jr. (Round Rock, TX); Aarthi Mahalingam (San Diego, CA); Jack Pryor (Ladera Ranch, CA)
Assignee: DexCom, Inc.
A61B5/14546A61B5/0031A61B5/1451A61B5/1473A61B5/1495A61B5/14532A61B5/14865A61B5/1468A61B5/1486A61B5/14503A61B5/14735A61B2560/0223Y02A90/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,743,801
App. No.
16/691,252
Granted
Aug 18, 2020
Kind
B2
Abstract

Systems and methods for processing sensor analyte data are disclosed, including initiating calibration, updating calibration, evaluating clinical acceptability of reference and sensor analyte data, and evaluating the quality of sensor calibration. The sensor can be calibrated using a calibration set of one or more matched sensor and reference analyte data pairs. Reference data resulting from benchtop testing an analyte sensor prior to its insertion can be used to provide initial calibration of the sensor data. Reference data from a short term continuous analyte sensor implanted in a user can be used to initially calibrate or update sensor data from a long term continuous analyte sensor.

Claims (26)

1. A glucose monitoring system comprising:

a transcutaneous electrochemical glucose sensor having an in vivo portion and an ex vivo portion;

a memory storing calibration information derived at least in part from an empirically derived relationship between in vitro sensitivity and in vivo sensitivity for the transcutaneous electrochemical glucose sensor; and

a processor configured to calibrate data generated by the transcutaneous electrochemical glucose sensor using the stored calibration information without reliance on any reference glucose measurements made after insertion of the in vivo portion of the transcutaneous electrochemical glucose sensor.

2. The glucose monitoring system of claim 1 , wherein the ex vivo portion of the transcutaneous electrochemical glucose sensor is in electrical communication with the processor.

3. The glucose monitoring system of claim 1 , wherein the empirically derived relationship between in vitro sensitivity and in vivo sensitivity is based at least in part on clinical trials.

4. The glucose monitoring system of claim 1 , wherein the calibration of the generated data relies at least in part on an in vitro sensitivity associated with the transcutaneous electrochemical glucose sensor, wherein the in vitro sensitivity is based at least in part on a comparison of a signal response of a plurality of transcutaneous electrochemical glucose sensors to a set of known glucose concentrations.

5. A method for calibrating data from a transcutaneous electrochemical glucose sensor, the method comprising:

receiving sensor data from the transcutaneous electrochemical glucose sensor after at least a portion of the transcutaneous electrochemical glucose sensor is inserted in a host, wherein the sensor data is indicative of a glucose concentration in the host; and

calibrating, using a processor, the sensor data received from the transcutaneous electrochemical glucose sensor,

wherein the calibrating comprises retrieving and using calibration information derived at least in part from each of in vitro testing, in vivo testing, and a relationship between in vitro sensitivity and in vivo sensitivity derived therefrom; and,

wherein the calibrating comprises not using reference glucose concentration values obtained after insertion of the at least a portion of the transcutaneous electrochemical glucose sensor into a host.

6. The method of claim 5 , wherein the relationship between in vitro sensitivity and in vivo sensitivity has been derived at least in part through an empirical process.

7. The method of claim 6 , wherein the empirical process relies on data obtained from clinical trials involving a plurality of transcutaneous electrochemical glucose sensors.

8. The method of claim 6 , wherein the empirical process involves calculating the in vivo sensitivity for each of the plurality of transcutaneous electrochemical glucose sensors.

9. A glucose monitoring system comprising:

a transcutaneous electrochemical glucose sensor having an in vivo portion and an ex vivo portion;

a memory storing calibration information derived at least in part from an empirically derived relationship between in vitro sensitivity and in vivo sensitivity for the transcutaneous electrochemical glucose sensor; and

an electronics unit configured to provide calibrated glucose information, wherein the electronics unit has been programmed to calibrate data generated by the transcutaneous electrochemical glucose sensor using the stored calibration information without reliance on any reference glucose measurements made after insertion of the in vivo portion of the transcutaneous electrochemical glucose sensor into a host.

10. The glucose monitoring system of claim 9 , wherein the ex vivo portion of the transcutaneous electrochemical glucose sensor is in electrical communication with the processor.

11. The glucose monitoring system of claim 9 , wherein the empirically derived relationship between in vitro sensitivity and in vivo sensitivity is based at least in part on clinical trials.

12. The glucose monitoring system of claim 9 , wherein the calibration of the data relies at least in part on an in vitro sensitivity associated with the transcutaneous electrochemical glucose sensor, wherein the in vitro sensitivity is based at least in part on a comparison of a signal response of a plurality of transcutaneous electrochemical glucose sensors to a set of known glucose concentrations.

13. A glucose monitoring device comprising:

a memory storing calibration information for a transcutaneous electrochemical glucose sensor, wherein the calibration information is derived at least in part from an empirically derived relationship between in vitro sensitivity and in vivo sensitivity;

a processor generating calibrated glucose information, wherein the calibrated glucose information is based at least in part on applying the stored calibration information to data generated by the transcutaneous electrochemical glucose sensor, without reliance on any reference glucose measurements made after insertion of an in vivo portion of the transcutaneous electrochemical glucose sensor into a host; and

a display providing the calibrated glucose information to a user.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: MAHALINGAM, AARTHI
To: DEXCOM, INC.
Reel/Frame 052808/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2019
From: GOODE, PAUL V., JR.; BRAUKER, JAMES H.; KAMATH, APURV ULLAS
To: DEXCOM, INC.
Reel/Frame 051131/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2019
From: PRYOR, JACK
To: DEXCOM, INC.
Reel/Frame 051132/0062 →
Continuity (8)
Continuation 16457628 · Jun 28, 2019
Continuation 15787595 · Oct 18, 2017
Continuation 15065623 · Mar 9, 2016
Continuation 13607162 · Sep 7, 2012
Continuation 12683755 · Jan 7, 2010
Continuation 11373628 · Mar 9, 2006
Provisional Application 60660743 · Mar 10, 2005
Related Publication 20200085355A1 · Mar 19, 2020
Cited By (4)
US 12,453,494 US 12,458,257 US 12,458,258 US 12,690,787